Crown jew­el from Ab­b­Vie's Cerev­el buy­out fails two Phase 2 schiz­o­phre­nia tests, Bris­tol My­er­s' stock soars

The cen­ter­piece of Ab­b­Vie’s $8.7 bil­lion Cerev­el ac­qui­si­tion just im­plod­ed.

Em­r­a­cli­dine, a schiz­o­phre­nia pro­gram ex­pect­ed to com­pete with the new­ly-ap­proved Coben­fy from Bris­tol My­ers Squibb …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER